Aimmune Therapeutics Stock News

Investors who take an interest in Aimmune Therapeutics, Inc. (NASDAQ:AIMT) should definitely note that the Independent...

JMP Securities downgraded shares of Aimmune Therapeutics (NASDAQ:AIMT) from an outperform rating to a market perform rating in a report issued on Wednesday morning, BenzingaRatingsTable reports. A num

Bank of Montreal Can boosted its stake in shares of Aimmune Therapeutics Inc (NASDAQ:AIMT) by 39.3% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 6,822 shares of t

AlphaCrest Capital Management LLC bought a new position in shares of Aimmune Therapeutics Inc (NASDAQ:AIMT) in the fourth quarter, according to the company in its most recent filing with the Securitie

Bad Week Gets Worse as Morning Rally Falters

Envestnet Asset Management Inc. raised its position in shares of Aimmune Therapeutics Inc (NASDAQ:AIMT) by 83.0% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 47,165 sh

Aimmune Therapeutics Inc (NASDAQ:AIMT) Director Patrick G. Enright acquired 125,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 18th. The shares were bought at a

Aimmune Therapeutics Inc (NASDAQ:AIMT) – Research analysts at Piper Sandler decreased their Q2 2020 earnings estimates for Aimmune Therapeutics in a research report issued on Monday, March 16th. Pip

The "Global Allergy Immunotherapy Market Analysis 2019" report has been added to ResearchAndMarkets.com's offering.

Aimmune Therapeutics (NASDAQ:AIMT)‘s stock had its “buy” rating reissued by equities research analysts at Wedbush in a report released on Wednesday, TipRanks reports. They currently have a $66.0

Aimmune Therapeutics Inc (NASDAQ:AIMT) – Piper Sandler cut their FY2024 EPS estimates for shares of Aimmune Therapeutics in a research report issued on Monday, March 16th. Piper Sandler analyst C. R

Wedbush analyst Liana Moussatos reiterated a Buy rating on Aimmune Therapeutics (AIMT) today and set a price target of $66.00. The company's shares closed

Wedbush analyst Liana Moussatos reiterated a Buy rating on Aimmune Therapeutics (AIMT – Research Report) today and set a price

The U.S. Food and Drug Administration on Wednesday recommended switching to virtual patient visits instead of in-person monitoring for clinical studies, as signs emerge that the rapid spread of the…

U.S.-based Iveric bio Inc delayed enrolment in a trial of its eye disease drug on Wednesday, two days after Provention Bio paused a study of its diabetes drug but allowed trial patients to complete th